|
A review on the latest clinical and laboratory criteria for clinical diagnosis of systemic sclerosis
|
Sedigheh Sharifzadeh   1, Fatemeh Fatemeh Nasri1 |
| 1- Shiraz University of Medical Sciences, School of Paramedical Sciences |
|
|
Abstract: (675 Views) |
Although systemic sclerosis is a heterogeneous disease, this condition should be suspected in any patient with Raynaud's phenomenon that begins or worsens near the time of antinuclear antibody detection, especially in patients with systemic sclerosis-specific autoantibodies, abnormal nail capillaries and the swollen fingers. The most common organ systems affected in systemic sclerosis are the skin, gastrointestinal tract, and lungs. In addition to a thorough history and physical examination, all patients with newly diagnosed systemic sclerosis should undergo a comprehensive serologic evaluation for systemic sclerosis-specific autoantibodies such as Anti centromere antibody (ACA), Anti RNA polymerase III antibodies, Anti Th/Th0, Anti PM/SCL antibodies and Anti topoisomerase antibodies and also a chest HRCT to screen for interstitial lung disease, and an echocardiogram to provide a baseline estimate of pulmonary artery pressure. In patients with interstitial lung disease, pulmonary function tests are also important to establish a baseline to monitor the progression of interstitial lung disease over time. If possible, referral to the scleroderma center is suggested for early diagnosis and classification of the disease and participation in clinical research studies.
|
|
| Keywords: systemic sclerosis, Raynaud's phenomenon, systemic sclerosis-specific autoantibodies, Anti centromere antibody (ACA), Anti RNA polymerase III antibodies |
|
|
Full-Text [PDF 990 kb]
(194 Downloads)
|
Type of Study: Review |
Subject:
ایمونولوژی و آلرژی
Received: 2024/06/23 | Accepted: 2024/06/23 | Published: 2024/06/23
|
|
|
|
|
|
|
| Add your comments about this article |
|
|
|
